BioCryst Pharmaceuticals Inc. [NASDAQ: BCRX] plunged by -$0.31 during the normal trading session on Monday and reaching a high of $8.725 during the day while it closed the day at $8.30. The company report on December 21, 2020 that BioCryst Announces Positive Phase 1 Results with BCX9250, an Oral ALK-2 Inhibitor for Treatment of Fibrodysplasia Ossificans Progressiva.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that in a Phase 1 clinical trial with BCX9250, an oral activin receptor-like kinase-2 (ALK-2) inhibitor discovered and developed by BioCryst for the treatment of fibrodysplasia ossificans progressiva (FOP), BCX9250 was safe and well tolerated at all doses studied, with linear and dose-proportional exposure supporting once-daily dosing.
FOP is an ultra-rare, severely disabling condition characterized by the irregular formation of bone outside the normal skeleton, also known as heterotopic ossification (HO). HO can occur in muscles, tendons and soft tissue. Patients with FOP become bound by this irregular ossification over time, with restricted movement and fused joints, resulting in deformities and premature mortality. There are currently no approved treatments for FOP.
BioCryst Pharmaceuticals Inc. stock has also loss -2.35% of its value over the past 7 days. However, BCRX stock has inclined by 120.16% in the 3 months of the year. Over the past six months meanwhile, it has gained 94.38% and gained 140.58% year-on date.
The market cap for BCRX stock reached $1.40 billion, with 176.52 million shares outstanding and 175.06 million shares in the current float. Compared to the average trading volume of 6.48M shares, BCRX reached a trading volume of 7826008 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about BioCryst Pharmaceuticals Inc. [BCRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BCRX shares is $10.56 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BCRX stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for BioCryst Pharmaceuticals Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on September 29, 2020. The new note on the price target was released on June 17, 2020, representing the official price target for BioCryst Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $7, while Barclays analysts kept a Overweight rating on BCRX stock. On November 15, 2019, analysts decreased their price target for BCRX shares from 5 to 4.
The Average True Range (ATR) for BioCryst Pharmaceuticals Inc. is set at 0.53, with the Price to Sales ratio for BCRX stock in the period of the last 12 months amounting to 26.09. The Price to Book ratio for the last quarter was 43.68, with the Price to Cash per share for the same quarter was set at 0.85.
BCRX stock trade performance evaluation
BioCryst Pharmaceuticals Inc. [BCRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.35. With this latest performance, BCRX shares gained by 99.04% in over the last four-week period, additionally plugging by 94.38% over the last 6 months – not to mention a rise of 158.57% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BCRX stock in for the last two-week period is set at 73.79, with the RSI for the last a single of trading hit 71.93, and the three-weeks RSI is set at 73.38 for BioCryst Pharmaceuticals Inc. [BCRX]. The present Moving Average for the last 50 days of trading for this stock 5.05, while it was recorded at 8.34 for the last single week of trading, and 4.18 for the last 200 days.
BioCryst Pharmaceuticals Inc. [BCRX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and BioCryst Pharmaceuticals Inc. [BCRX] shares currently have an operating margin of -203.66 and a Gross Margin at +91.60. BioCryst Pharmaceuticals Inc.’s Net Margin is presently recorded at -222.99.
Return on Total Capital for BCRX is now -85.02, given the latest momentum, and Return on Invested Capital for the company is -135.90. Return on Equity for this stock declined to -248.94, with Return on Assets sitting at -67.61. When it comes to the capital structure of this company, BioCryst Pharmaceuticals Inc. [BCRX] has a Total Debt to Total Equity ratio set at 221.30. Additionally, BCRX Total Debt to Total Capital is recorded at 68.88, with Total Debt to Total Assets ending up at 48.30. Long-Term Debt to Equity for the company is recorded at 116.84, with the Long-Term Debt to Total Capital now at 36.37.
Reflecting on the efficiency of the workforce at the company, BioCryst Pharmaceuticals Inc. [BCRX] managed to generate an average of -$777,836 per employee. Receivables Turnover for the company is 3.69 with a Total Asset Turnover recorded at a value of 0.30.BioCryst Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 1.50.
Earnings per share (EPS) analysis for BioCryst Pharmaceuticals Inc. [BCRX] stock
With the latest financial reports released by the company, BioCryst Pharmaceuticals Inc. posted -0.02/share EPS, while the average EPS was predicted by analysts to be reported at -0.26/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 92.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BCRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BioCryst Pharmaceuticals Inc. go to 19.90%.
BioCryst Pharmaceuticals Inc. [BCRX]: Insider Ownership positions
There are presently around $1,051 million, or 72.80% of BCRX stock, in the hands of institutional investors. The top three institutional holders of BCRX stocks are: STATE STREET CORP with ownership of 16,183,973, which is approximately 3.887% of the company’s market cap and around 0.20% of the total institutional ownership; BLACKROCK INC., holding 15,943,893 shares of the stock with an approximate value of $132.33 million in BCRX stocks shares; and BAKER BROS. ADVISORS LP, currently with $105.38 million in BCRX stock with ownership of nearly -7.777% of the company’s market capitalization.
Positions in BioCryst Pharmaceuticals Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 85 institutional holders increased their position in BioCryst Pharmaceuticals Inc. [NASDAQ:BCRX] by around 14,142,805 shares. Additionally, 77 investors decreased positions by around 20,236,202 shares, while 24 investors held positions by with 92,274,818 shares. The mentioned changes placed institutional holdings at 126,653,825 shares, according to the latest SEC report filing. BCRX stock had 26 new institutional investments in for a total of 1,955,098 shares, while 32 institutional investors sold positions of 2,984,438 shares during the same period.